Goldman schreef op 1 november 2021 11:50:
De stijging deels te danken aan het positief advies van afgelopen week
H.C. Wainwright Thinks Pharming Group’s Stock is Going to RecoverChristine Brown
Oct 28, 2021, 03:15 PM
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of $37.00. The company’s shares closed last Wednesday at $9.61, close to its 52-week low of $9.02.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 7.6% and a 36.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pharming Group with a $37.00 average price target.
See today’s best-performing stocks on TipRanks >>Based on Pharming Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $41.26 million
and net profit of $4.85 million. In comparison, last year the company earned revenue of $39.3 million and had a net profit of $9.72 million.